University of Minnesota. Driven to Discover.
(CIDRAP News) – A vaccine designed to offer protection against many strains of influenza viruses appeared safe in low doses and triggered a satisfactory immune response in a phase 1 clinical trial, the vaccine's developer announced recently.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2021 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.